Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ectericid (Ekterytsyd) is an antiseptic and disinfectant agent of natural origin, derived from the water-soluble oxidation products of fish oil (containing a mixture of carbonyl compounds, peroxides, and aldehydes) in an isotonic sodium chloride solution. Developed and manufactured by Biolik Pharma (formerly Farmstandart-Biolik) in Ukraine, Ectericid exhibits broad-spectrum antibacterial activity against pyogenic microflora, including Pseudomonas aeruginosa, Escherichia coli, Proteus spp., and Staphylococcus aureus (including antibiotic-resistant strains). It is primarily used topically for the treatment of postoperative and traumatic wounds complicated by purulent infections, slow-healing wounds, furuncles, carbuncles, fistulous forms of osteomyelitis, burns, and trophic ulcers with suppuration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ectericid.